Biotech Values

[DewDiligence]

>Probably part of the reason for the large late trade in MNTA.<

Could be, but some of the provisions in the bill might be construed as bearish for MNTA.

E.g., a worrywart might interpret the language requiring clinical trials for a FoB but allowing the FDA to waive the requirement as being harsher than merely saying that the need for clinical trials is left to the FDA’s discretion.